India is poised to establish itself as a pivotal hub for semaglutide API manufacturing. Leading pharmaceutical firms are amplifying their production capabilities to seize a significant stake in the expanding international market for obesity and diabetes treatments. With the expiration of semaglutide’s exclusivity, India finds itself in a prime position to spearhead advancements in underserved markets.
